← All trials
NCT06692491
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2025
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2029
- First posted
- Nov 18, 2024
- Last posted
- Nov 18, 2024
- Enrollment
- 200
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Peking UniversityLead sponsor
- Peking UniversitySponsor investigator
- Peking UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.